NCT06629779From ClinicalTrials.govRecruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

Metastatic Castration-Resistant Prostate Cancer

At a glance

Phase: Phase 3
Study type: Interventional
Sponsor: Pfizer
Enrolment target: 900
Started: 22 October 2024
Main results due: 2 December 2026
Study sites: 233
Registry updated: 25 September 2026

Can you take part?

Aged 18 years and over.
Men only.
You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria

Inclusion Criteria:

* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
* Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
* Progressive disease in the setting of medical or surgical castration.
* ECOG performance status 0 or 1, with a life expectancy of ≥12 months as assessed by the investigator.

Exclusion Criteria:

* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that make the participant inappropriate for the study.
* Known history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery.
* Clinically significant cardiovascular disease.
* Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure.
* Any history of myelodysplastic syndrome, acute myeloid leukemia, or any other prior malignancy with a few exceptions.
* Participants must be treatment naïve at the mCRPC stage, eg, no cytotoxic chemotherapy, radio-ligand therapy (i.e. 177Lu- PSMA-617), CDK4/6 inhibitors, 5-alpha reductase inhibitors for prostate cancer in any setting, androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment with the following exceptions:

1. Treatment with first-generation antiandrogen (ADT) agents, estrogens, progestins, cyproterone acetate;
2. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion.
* Previous administration with an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is longer).
* Inadequate organ function.

What this study is about

In the sponsor’s own words, from the registry.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Study sites(233)

Ironwood Cancer & Research Centers
Chandler, Arizona, United States
Recruiting
Ironwood Cancer & Research Centers
Gilbert, Arizona, United States
Recruiting
Palo Verde Hematology Oncology
Glendale, Arizona, United States
Recruiting
Ironwood Cancer & Research Centers
Glendale, Arizona, United States
Recruiting
Ironwood Cancer & Research Centers
Goodyear, Arizona, United States
Recruiting
Ironwood Cancer & Research Centers
Mesa, Arizona, United States
Recruiting
Ironwood Cancer & Research Centers
Mesa, Arizona, United States
Recruiting
Ironwood Cancer & Research Centers
Phoenix, Arizona, United States
Recruiting
Ironwood Cancer & Research Centers
Scottsdale, Arizona, United States
Recruiting
Highlands Oncology
Fayetteville, Arkansas, United States
Recruiting
Arkansas Urology - Little Rock
Little Rock, Arkansas, United States
Recruiting
Highlands Oncology
Rogers, Arkansas, United States
Recruiting
Highlands Oncology Group
Springdale, Arkansas, United States
Recruiting
Los Angeles Cancer Network (LACN)
Anaheim, California, United States
Recruiting
Los Angeles Cancer Network (LACN)
Fountain Valley, California, United States
Recruiting
Los Angeles Cancer Network (LACN)
Glendale, California, United States
Recruiting
Los Angeles Cancer Network (LACN)
Glendale, California, United States
Recruiting
Los Angeles Cancer Network (LACN)
Laguna Hills, California, United States
Recruiting
Los Angeles Cancer Network (LACN)
Los Angeles, California, United States
Recruiting
Los Angeles Cancer Network (LACN)
Los Angeles, California, United States
Recruiting
Medical Oncology Associates of San Diego
San Diego, California, United States
Recruiting
Blessing Hospital
Quincy, Illinois, United States
Recruiting
Blessing Physician Services
Quincy, Illinois, United States
Recruiting
Adult & Pediatric Urology, PC
Omaha, Nebraska, United States
Recruiting
CHRISTUS St. Vincent Regional Cancer Center
Santa Fe, New Mexico, United States
Recruiting
Montefiore Medical Center - Medical Park
The Bronx, New York, United States
Recruiting
Montefiore Medical Center
The Bronx, New York, United States
Recruiting
AUC Urologists, LLC
Myrtle Beach, South Carolina, United States
Recruiting
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina, United States
Recruiting
Grand Strand Medical Center
Myrtle Beach, South Carolina, United States
Recruiting
Parkway Surgery Center
Myrtle Beach, South Carolina, United States
Recruiting
USA Clinical Trials
San Antonio, Texas, United States
Recruiting
Northwest Medical Specialties, PLLC
Bonney Lake, Washington, United States
Recruiting
Northwest Medical Specialties, PLLC
Federal Way, Washington, United States
Recruiting
Northwest Medical Specialties, PLLC
Gig Harbor, Washington, United States
Recruiting
Northwest Medical Specialties, PLLC
Puyallup, Washington, United States
Recruiting
Harborview Medical Center
Seattle, Washington, United States
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Recruiting
University of Washington Medical Center - Montlake
Seattle, Washington, United States
Recruiting
Northwest Medical Specialties, PLLC
Tacoma, Washington, United States
Recruiting
Centro de Urología (CDU)
CABA, Buenos Aires, Argentina
Recruiting
Hospital Sirio Libanes
Capital Federal, Buenos Aires, Argentina
Recruiting
Imagenes Mdq
Mar del Plata, Buenos Aires, Argentina
Recruiting
Instituto de Investigaciones Clínicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina
Recruiting
Centro Medico Privado CEMAIC
Capital, Córdoba Province, Argentina
Recruiting
IMAXE
Buenos Aires, Argentina
Recruiting
Centro Medico Fleischer
Buenos Aires, Argentina
Recruiting
Hospital Privado Centro Médico de Córdoba
Córdoba, Argentina
Recruiting
Oncocentro Servico Medicos e Hospitalares Ltda
Fortaleza, Ceará, Brazil
Recruiting
Hospital São Carlos
Fortaleza, Ceará, Brazil
Recruiting
Oncocentro Oncologia
Fortaleza, Ceará, Brazil
Recruiting
Instituto D'Or de Pesquisa e Ensino
Fortaleza, Ceará, Brazil
Recruiting
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Recruiting
Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador
Salvador, Estado de Bahia, Brazil
Recruiting
Clinica Amo - Rio Vermelho
Salvador, Estado de Bahia, Brazil
Recruiting
Clinica Amo - Rio Vermelho
Salvador, Estado de Bahia, Brazil
Recruiting
Hospital Sirio Libanes
Brasília, Federal District, Brazil
Recruiting
Liga Norte Riograndense Contra o Câncer
Natal, Rio Grande do Norte, Brazil
Recruiting
Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Recruiting
MedPlex Eixo Norte
Porto Alegre, Rio Grande do Sul, Brazil
Recruiting

Showing 60 of 233 sites — filter to narrow it down. 221 of the 233 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT06629779. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me